Abstract: The traditional high-throughput sequencing technology obtained after phenotyping analysis of tumor patients only represents the average phenotype of most cells, so a large amount of information will inevitably be lost. In order to make up for this shortcoming, single cell sequencing (SCS) technology arises at the right moment. As a revolutionary technology, it can analyze individual cells to gain insight into the differences in the microenvironment between tumor cells, and help the development of tumor targeted drugs. At present, this technology has been applied to a variety of lymphomas, including Hodgkin's lymphoma and non-Hodgkin's lymphoma, and shows great clinical application value.

Key words: lymphoma, sequence analysis, single cell sequencing, tumor heterogeneity